Coronary artery thrombolytic agent for acute myocardial infarction

Abstract

The invention discloses a coronary artery thrombolytic agent for acute myocardial infarction. The coronary artery thrombolytic agent is prepared from, by weight, 0.5-2 parts of tirofiban, 5-10 parts of bivalirudin, 3-5 parts of tenecteplase, 0.4 part of sodium nitroprusside, 0.0032 part of unfractionated heparin and the balance normal saline, and the normal saline is used for diluting the mixture to obtain the volume which is 10 times of the original volume. Researches show that great advantages are brought when antiplatelet and anticoagulant drugs are administrated in a coronary artery based on PCI treatment, local drug concentration is high according to drug administration in the coronary, the needed thrombolytic drug dosage is small, thrombolysis is fast, the success rate is high, and few of hemorrhagic complications are caused. The coronary artery thrombolytic agent is used in cooperation with the intranperative radiography or intracavity radiological technology, thrombus changes can be dynamically monitored in real time, the best microthrombus dissolving effect is achieved, the PCI intraoperative no-reflow occurrence rate is lowered, and the prognosis of a patient is significantly improved.

Description

Technical field [0001] The invention belongs to the field of medicinal solutions applied to the body, and relates to acute myocardial infarction, and in particular to a coronary artery thrombolytic agent for acute myocardial infarction. Background technique [0002] The main cause of acute myocardial infarction (myocardial infarction, MI) is coronary artery occlusion caused by unstable plaque rupture and acute thrombosis, causing partial myocardial necrosis due to severe and persistent ischemia. The existing treatment methods include intravenous thrombolysis, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) and so on. However, intravenous thrombolysis has poor efficacy and many bleeding complications. Even if thrombus aspiration is used during PCI, there are still a large number of microthrombi that cannot be removed by mechanical treatment. CABG in the acute phase of MI has a high risk and large surgical trauma. Therefore, it is urgent to find new t...

AI Technical Summary

Problems solved by technology

However, the curative effect of intravenous thrombolysis is poor, and there are many bleeding complications; even if thrombus aspiration is used during PCI, there are still a large number of microthrombi that cannot be removed by mechanical therapy; the risk of CABG in the acute stage of MI is high, and the surgical trauma is large

Images